![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sucampo Receives $20 Million From Takeda for Milestone
Sucampo Receives $20 Million From Takeda for Milestone
May 17, 2005
Sucampo Pharmaceuticals (Sucampo), a leader in functional fatty acid research and development, announced that it received $20 million from its business partner, Takeda Pharmaceutical Company (Takeda), as payment for achieving a development milestone -- initiation of a Phase III clinical trial of lubiprostone to treat patients with constipation-predominant irritable bowel syndrome (IBS-C). Lubiprosotone, one of the Sucampo's proprietary agents, is a new class of functional fatty acid that produces chloride channel-opening activity.
DrugNewswire (http://www.drugnewswire.com/670/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct